Repligen: resin recovery feature a ‘differentiator’ in chromatography space

By Dan Stanton contact

- Last updated on GMT

The OPUS R resin unpacking port. Image: c/o Repligen
The OPUS R resin unpacking port. Image: c/o Repligen

Related tags: Chromatography, Revenue

A resin recovery feature being added to its larger prefilled chromatography columns offers an ‘insurance policy’ for drugmakers, says Repligen.

Bioprocessing technology and Protein A ligand supplier Repligen published its third quarter 2016 financials last week, and reported a 25% y-o-y rise in product revenue to $24.7m, attributed in part to sales of its OPUS-branded chromatography columns.

And sales of the prefilled offering are expected to continue to rise, the firm said, driven by a new resin recovery feature on its 45cm and 60cm which - according to spokeswoman Sondra Newman - positions Repligen alone amongst the main chromatography tech vendors.

“OPUS R columns feature a side port through which chromatography resins can be removed, following a defined protocol,”​ she told Biopharma-Reporter, adding the feature serves two main purposes.

“As an insurance policy to lower risk in the event of any process deviations - for example, accidental over pressurizing a column – [and it] gives flexibility to the end user to use resin after a campaign is finished for engineering, scale down and reuse of studies in process development.”

Her comments echoed CEO’s Tony Hunt who described the feature as “a differentiator in the whole pre-packing space”​ during a conference call last week. However, he also told stakeholders there will be a price increase associated with the new feature.

But according to Newman “the price increase will be nominal. The strategy with OPUS R is more focused on providing an important differentiator that our customers have been asking for.”

The feature – which was first launched at Biotech Week in Boston last month​ – will be standard on the two larger diameter Opus columns, as these represent where the resin investment is most significant, and will be implanted by the second quarter 2017.

Related news

Show more

Related products

show more

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...


Inline concentration improves process economics

Pall Biotech | 15-Jun-2018 | Case Study

Would you like to enhance your downstream process, increase production capacity and reduce costs? This case study application note demonstrates how implementing...

Related suppliers

Follow us


View more